Logo

TOMZ

TOMI Environmental Solutions, Inc.

TOMZ

TOMI Environmental Solutions, Inc. NASDAQ
$0.79 -4.82% (-0.04)

Market Cap $15.82 M
52w High $1.50
52w Low $0.63
Dividend Yield 0%
P/E -3.04
Volume 16.03K
Outstanding Shares 20.03M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.012M $1.485M $-450.348K -22.388% $-0.02 $-251.421K
Q2-2025 $1.031M $1.81M $-1.238M -120.017% $-0.062 $-1.023M
Q1-2025 $1.577M $1.706M $-255.593K -16.212% $-0.013 $-28.792K
Q4-2024 $1.069M $2.62M $-3.256M -304.527% $-0.16 $-3.035M
Q3-2024 $2.542M $1.412M $58.962K 2.319% $0.003 $261.82K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $490.022K $8.045M $5.839M $2.206M
Q2-2025 $569.45K $8.476M $5.819M $2.657M
Q1-2025 $674.181K $9.958M $6.114M $3.843M
Q4-2024 $664.879K $9.694M $5.595M $4.099M
Q3-2024 $809.037K $12.462M $5.107M $7.355M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-450.348K $-113.478K $-65.95K $100K $-79.428K $-113.48K
Q2-2025 $-1.238M $-187.604K $-67.127K $150K $-104.731K $-190.269K
Q1-2025 $-255.593K $-275.698K $0 $285K $9.302K $-275.698K
Q4-2024 $-3.256M $12.709K $-156.867K $0 $-144.158K $-144.158K
Q3-2024 $58.962K $105.311K $-5.384K $0 $99.927K $99.927K

Revenue by Products

Product Q3-2023Q4-2023Q2-2025Q3-2025
Product and Service Revenue
Product and Service Revenue
$0 $0 $0 $0
International
International
$0 $0 $0 $0
Service And Training
Service And Training
$0 $0 $0 $0
SteraMist PRoduct
SteraMist PRoduct
$0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement TOMI’s income statement shows a very small revenue base that has not grown meaningfully in recent years and actually appears lower than during the pandemic peak. Gross profit is thin, operating expenses absorb most of the revenue, and the company has been losing money per share for several years after briefly turning a profit earlier in the period. Overall, this looks like an early-stage or niche business that has not yet converted its technology and contracts into consistent, profitable scale.


Balance Sheet

Balance Sheet The balance sheet is light, with modest total assets, limited cash, and no meaningful debt. Equity remains positive but small, reflecting a thin capital cushion. The absence of debt reduces financial pressure, but the modest asset and cash levels also mean TOMI does not have a large buffer to absorb prolonged losses or major setbacks without raising additional capital or improving its operating performance.


Cash Flow

Cash Flow Cash flows from operations and free cash flow have hovered around breakeven to modestly negative levels, indicating that the business has not yet generated strong, self-funding cash generation. Capital spending is minimal, which helps conserve cash but also suggests constrained investment capacity. The company’s future flexibility will depend heavily on its ability to ramp revenue and margin, or on access to external funding, rather than on internally generated cash.


Competitive Edge

Competitive Edge TOMI operates in a crowded disinfection and decontamination market but differentiates itself with its proprietary Binary Ionization Technology and SteraMist platform. Key strengths include strong efficacy, non-corrosive performance that is friendly to sensitive equipment, regulatory validation as a hospital-grade disinfectant, and the shift toward integrated, custom-engineered systems embedded in customer facilities and equipment. However, it competes with much larger, well-funded players such as STERIS and Ecolab, which enjoy broad product portfolios, strong customer relationships, and scale advantages. TOMI’s moat is therefore niche and application-specific: strongest where its ionized hydrogen peroxide and embedded systems solve problems that traditional vapor systems handle less efficiently or more disruptively.


Innovation and R&D

Innovation and R&D The company is clearly innovation-driven, centered on its BIT-powered SteraMist technology and a growing range of specialized delivery formats: handheld units, room systems, backpack systems, decontamination boxes, and fully integrated systems. Recent focus on custom engineered and integrated systems for cleanrooms, laboratories, and life-science environments points to R&D aimed at embedding the technology directly into critical infrastructure. TOMI is also working on expanding recurring revenue through consumables, service contracts, and a service-provider network. The innovation agenda appears focused less on entirely new chemistry and more on new applications, system designs, and partnerships that make its existing technology easier to adopt, automate, and use regularly.


Summary

TOMI Environmental Solutions combines a distinctive, well-regarded disinfection technology with a very small, still-unprofitable financial profile. The business has yet to scale revenue or earnings in a consistent way, and its modest balance sheet and weak cash generation underline execution and funding risks if growth stalls. On the strategic side, its proprietary ionized hydrogen peroxide platform, regulatory approvals, and emphasis on integrated systems and life-sciences partnerships create a targeted competitive edge in specific, high-requirement settings. The core question for the future is whether TOMI can convert its strong technical story and integration pipeline into sustained commercial traction, recurring revenue, and ultimately a more robust and self-sustaining financial base, while competing against much larger industry incumbents.